All posts by imreal

Health

The 12th Annual Breast Reconstruction Awareness Day USA returns Oct. 18 to Increase Recognition of Patient Options with Education, Events and Fundraisers

Leave a comment


Breast reconstruction is shown to improve patients’ psychological, social and sexual well-being along with improving their quality of life following a mastectomy or lumpectomy. Patients deserve full and accurate information; empowering them to make the best decisions for their bodies. BRA Day promotes educating patients on the full range of options available to them so they can reclaim their bodies in a way that best supports their goals.

“The objective is to get patients who are adjusting to a new body comfortable again in their clothes and skin in a way that best serves them,” said Dr. Howard Levinson, MD, president of The PSF. “The significance of BRA Day is to make sure patients have both awareness and access to all their options to make the most well-informed choice that serves their unique needs.”

BRA Day is a movement that seeks to reduce obstacles in public education, patient care and research. BRA Day events worldwide bring attention to the varied options and procedures available and provides information to patients and their supporters so they can make informed decisions about their care. BRA Day efforts involve informing patients, family, caregivers, and media that the breast cancer loop remains open until a woman is informed of breast reconstruction options. BRA Day events are happening throughout the United States on Oct. 18 to raise money to support research and grants. ASPS and The PSF launched the Breast Reconstruction Awareness Campaign and the annual BRA Day USA in 2012. The inaugural BRA Day started in Canada in 2011.

The BRA Campaign has raised approximately $115,552 this year through the support of Diamond sponsor Allergan Aesthetics, an AbbVie company, campaign sponsors CareCredit and Integra Foundation and the many regional and local events. These contributions to the National BRA Fund support vital research, charitable giving and awareness grants.

The movement doesn’t end there. Other fundraising efforts include the CareCredit donation program. CareCredit will donate $1 to the Breast Reconstruction Awareness campaign every time a CareCredit cardholder purchases $200 or more on their card with an ASPS-member surgeon in the CareCredit network during October.

Capping off the month of awareness and support, the Breast Reconstruction Awareness 5K will take place on Saturday, Oct. 28, at 7:00 a.m. in Brush Square Park in Austin, TX, during Plastic Surgery The Meeting 2023. Participants can choose to run in person, virtually or show their support with literally no sweat by fundraising. Learn more and sign up at: https://www.plasticsurgerythemeeting.com/events.

About Breast Reconstruction
Studies show that women who undergo breast reconstruction experience significant improvements in psychological, social and sexual well-being. Every patient deserves to learn about the full complement of breast reconstruction options at the time of diagnosis. In fact, the two main reasons women do not undergo breast reconstruction are because they are not referred to plastic surgeons and are not informed of their reconstructive options. Breast reconstruction is part of a comprehensive approach and treatment for breast cancer patients.

Integral to this cohesive team approach, are frequent meetings that occur to discuss each patient and her individualized treatment plan. Members of this group of specialists are oncologist, radiologists, plastic surgeons, breast surgeons, plastic pathologists, radiation oncologists, geneticists, nurses, patient care coordinators and more. Their collective insights guarantee that patients are not only aware of but also have access to a full range of reconstructive procedures, with decisions based on consensus among the team and ultimately the patient.

“Women need choices – they should be presented with the complete range of breast reconstruction options,” said Lynn Damitz, MD, ASPS Board Vice President of Health Policy & Advocacy. “Shared decision-making is the optimal goal where we are all part of the decision.”

For more information on breast reconstruction, visit http://www.breastreconusa.org. Become educated and help educate others about the availability of and access to breast reconstruction and why all women deserve a team approach to breast cancer treatment.

About ASPS
The American Society of Plastic Surgeons (ASPS) is the largest organization of board-certified plastic surgeons in the world. Representing nearly 8,000 physician members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 92 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.

About The PSF
The Plastic Surgery Foundation (The PSF), founded in 1948, supports research, international volunteer programs and visiting professor programs. The foundation’s mission is to improve the quality of life of patients through research and development. The PSF accomplishes its mission by providing invaluable support to the research of plastic surgery sciences through a variety of grant programs. The PSF works in concert with the American Society of Plastic Surgeons (ASPS).

Media Contact

Niccole Caan, American Society of Plastic Surgeons, 847-228-3333, [email protected], www.plasticsurgery.org

SOURCE American Society of Plastic Surgeons

Society: Social Services

Chicago Nonprofit Legacy Leaders International Hosts Inaugural Sneaker Gala to Empower Next Generation of Leaders; Fundraiser and Silent Auction aims to raise $40,000

Leave a comment


Everett Gutierrez Jr., the foundation’s present and founder, executive coach at Everett Empowers, entrepreneur and author has a passion for developing potential in others. The Legacy Fellows Program (for young adults ages 21-30) helps leaders of color achieve financial independence and life balance by discovering their purpose, developing business opportunities, and creating a network of success that creates generational wealth.

“I can’t say this enough, but I love my Fellows and the work we are doing at Legacy Leaders to change the narrative of these young people,” Gutierrez said. “Some are getting promotions, others going back to school, starting a business or changing their relationship patterns.”

This is Legacy Leaders first ever Sneaker Gala and all guests are encouraged to wear their best sneakers and dress in style. Guests are also encouraged to wear special masks for the masquerade themed gala.

The evening will be co-hosted by Dr. Tanjie Brewer, the charismatic founder and CEO of Stylish & Fit, and Dr. David Wardman, dedicated founder and CEO of Warman Way and Balanced ChiroMed. Both hosts Brewer and Wardman are passionate about wellness and living a healthy lifestyle.

Renowned celebrity Chef Jewel Robinson will be creating culinary masterpieces and providing an elevated refreshment experience for the event. Entertainment will include Tiffany Hines, a talented singer known for her soulful voice and captivating performances among others.

A silent auction featuring trips to Bali, Mexico, and Italy to facials, life couching, and signed sports memorabilia from Chicago teams like the Bears, Blackhawks, and Bulls. Registrations for bids are now open and will run until the event day.

The Legacy Sneaker Gala will be an enchanting night with promises to celebrate leadership, fashion, community, and the remarkable impact that can be created by investing in young adults. One of the Legacy Fellows, Brandon T. Griffin, a security guard and aspiring musical artist, shared what being part of the program means to him.

“For me, being part of Legacy Leaders means setting an example for the future generations and showcasing what it means to be a true and real leader,” he said. “I am surrounded by a community of like-minded people and it’s inspiring to see us grow and support each other.”

The funds received during the gala will go directly towards the foundation to continue growing and proving more programs and resources for young adults.

Legacy Leaders has also received a matching grant of up to $40,000 from a dedicated partner meaning that all proceeds collected from tickets, auctions, raffles and other contributions will be doubled. Gala tickets, donations, and silent auction bids can more information can be purchased and found this link.

Gutierrez said that the public can help by donating to the foundation or paying it forward and purchasing a ticket for young adults interested in attending: https://www.mylegacyleaders.org/.

Gutierrez remarked: “This is ground breaking legacy work, and I hope people don’t miss the opportunity to get involved and donate or purchase tickets to the gala. It’s all in the name of our future!”

About Legacy Leaders International:
Legacy Leaders International provides training and life-transforming experiences that create a ripple effect of world changers. Since its inception in 2010, Legacy Leaders has played a critical role in equipping individuals from black and brown communities with the confidence and skills to prepare them for more significant opportunities. With a passion for developing potential in others, Legacy Leaders believes that everyone can advocate and create change in their own lives and surroundings. Through collaborations with other partner organizations, they work to create experiences that help propel teens, college-age students, and young adults to succeed in all of their endeavors. The foundation of the organization focuses on assessing an individual’s history and circumstances to identify growth opportunities, transforming their future.

Media Contact

Marie Lazzara, JJR Marketing, 630-400-3361, [email protected], www.jjrmarketing.com

SOURCE Legacy Leaders International

health and fitness

TrialAssure Uses Artificial Intelligence to Create Plain Language Summaries for 50,000 Studies Listed on ClinicalTrials.Gov

Leave a comment


Plain language summaries, a regulatory requirement elsewhere in the world, are meant to provide the public with the results of a clinical trial in a way that is more easily understood (i.e., 6th-8th grade reading level). While still voluntary in the United States, there has been increased public outcry for transparency in the pharmaceutical industry and these plain language summary documents are required in the European Union (EU) under the EU Clinical Trial Regulation No. 536/2014.

This comes at a time when just 12 percent of Americans are considered proficient in their health literacy, according to the National Assessment of Adult Literacy, and most recent research out of the NIH shows that only about 14 percent of plain language summaries are available to clinical trial participants.

How does this help patient engagement?

“These health literacy numbers need to improve, and one way forward is to share information in formats that are accessible. AI-led technology like TrialAssure LINK will help the medical community, including researchers in biopharma, to more clearly communicate with participants and their families as to the results of the clinical trials and also increase treatment options. This initiative recognizes the importance of our collaboration, especially during Health Literacy Month this October,” said Prasad M. Koppolu, Chief Operating Officer, TrialAssure.

Koppolu continued, “By using TrialResults.com, we have charged past the lack of a current mandate for reporting these plain language summary documents and taken a step forward, posting understandable clinical trial results to help improve health literacy and give the entire pharmaceutical industry an opportunity to be more transparent.”

Plain language summaries help patients, their families, and the public at large by:

  • providing a better understanding of the clinical study that occurred,
  • giving more context and details around what the individual studies accomplished, or didn’t accomplish, and
  • helping them understand the value of personal contributions to science and empowering clinical trial participants to continue to be involved in clinical trials in the future.

On the TrialResults.com website, the public can learn about specific clinical trials for diseases or conditions of interest. Reading one of the approximately 50,000 plain language summaries available provides a starting point to understand the clinical trial at a high level – just enter a disease, condition, or study number in the search bar. The study sponsor will always be listed in the summary, making it easy for individuals to find direct and additional information on the sponsor website.

The plain language summary documents will be released on TrialResults.com in the following five groupings by condition and/or disease:

  • Oncology (available now)
  • Metabolic
  • Mental Health and Neurological
  • Respiratory
  • All others

To be notified when additional summaries are posted, email [email protected] to be added to the mailing list.

Reviewing the ClinicalTrials.gov record for further supporting data and understanding is recommended and a link will be available on TrialResults.com for each record. It should be emphasized that a physician should be consulted before making any healthcare decisions.

Saving one million hours by using AI to create 50,000 plain language summaries

“Three factors are converging in 2023 – the rise of public-facing generative AI technology, a resurgence in transparency initiatives with global health authorities, and mounting concerns related to health literacy despite major technological and scientific advances in recent decades,” said Zach Weingarden, Director of Product Solutions, TrialAssure.

Weingarden continues, “Plain language summary documents are notoriously time-consuming and can be challenging to write, and many pharmaceutical companies struggle to juggle resources between this and writing the required clinical study reports, completing other disclosure requirements, and filing their new drug applications. AI has the potential to turbocharge the initial drafting of these documents, automatically and in bulk, saving the skilled reviewers’ effort for a quick confirmation and finalization step. We have demonstrated this is possible by creating fully written drafts based solely upon data already available in public records.”

When manually drafting a plain language summary in the pharmaceutical industry, it takes approximately 20 hours per document to write from scratch. If this estimate is accurate, to draft 50,000 plain language summary documents would take approximately 1,000,000 hours. TrialAssure was able to reduce this workload to less than one day. Time, effort and cost no longer remain an excuse for transparency.

Accuracy of AI-generated plain language summary documents

“We hope this exercise will show that these AI-generated drafts are a great start, but AI has limited abilities and the use of AI is not a complete replacement of a skilled human writer,” said Weingarden. “Furthermore, we are limited to the data that is available in the ClinicalTrials.gov record. Depending on the structure and format of the data, it may be difficult for the AI to interpret and summarize accurately. We expect this to be an insightful demonstration of a committed path forward towards transparency, harvesting the scalable power and working to improve the limitations of our AI technology and welcome feedback from the scientific community.”

Feedback on the plain language summaries posted to TrialResults.com and generated by TrialAssure’s LINK application can be emailed to [email protected] and will help improve the quality of the plain language summaries.

With industry feedback incorporated and further Sponsor collaboration, TrialAssure will look to implement a new process in the near future that will use AI to automatically generate a plain language summary whenever a new record is available. This will scan ClinicalTrials.gov data daily, allowing new plain language summary documents to be available on TrialResults.com in near real-time.

Search the database at www.trialresults.com.

About TrialAssure

TrialAssure, Inc. is a leading, global clinical trial disclosure and data transparency provider with unmatched experience in helping navigate complex regulatory compliance challenges. TrialAssure provides fast, affordable, and intelligent software and service solutions to facilitate clinical trial disclosure (registration and results reporting), document and data anonymization, and enhanced patient engagement, while delivering the highest quality clinical trial transparency deliverables that exceed the most stringent requirements. Established in 2009, TrialAssure regularly adapts to ever-changing clinical trial disclosure and data transparency requirements and was named Data Solution of the Year – Healthcare in the Data Breakthrough Awards.

For more information, visit www.trialassure.com

Media Contact

Don F. McLean, TrialAssure, 1 7347164182, [email protected], www.trialassure.com 

SOURCE TrialAssure

Health: Mental Health

Hammes Healthcare celebrates completion of OhioHealth Grant Cancer Center

Leave a comment


Construction on the project began in March of 2022 with the center opening to patients in September 2023.

“We’re proud to have supported OhioHealth with this complex project,” said Adam Novak, Hammes Healthcare Vice President. “The new center will provide greater ease and convenience for patients in need of comprehensive cancer care in downtown Columbus.”

Hammes Healthcare has served as OhioHealth’s owner’s representative and project manager on more than 30 projects over the past 11 years. Hammes is currently engaged on the new OhioHealth Women’s Center and OhioHealth Trauma and Critical Care Center at Grant, both of which were announced earlier this year.

About Hammes Healthcare
Hammes Healthcare is a national consulting firm that provides real estate and market strategy, facility planning, project management and development services to the healthcare industry. As a reflection of its commitment to the healthcare industry, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 25 consecutive years—including 20 years as No. 1—and by Revista’s Outpatient Healthcare Real Estate Development Report. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. https://www.hammes.com/

Media Contact

Katherine Murray, Hammes, 414.509.2595, [email protected], https://www.hammes.com/

SOURCE Hammes Healthcare

Health

The Healthcare Technology Report Announces The Top 100 Healthcare Technology Companies of 2023

Leave a comment


The Healthcare Technology Report is pleased to announce The Top 100 Healthcare Technology Companies of 2023.

NEW YORK, Oct. 18, 2023 /PRNewswire-PRWeb/ — The Healthcare Technology Report is pleased to announce The Top 100 Healthcare Technology Companies of 2023. In recent decades, the realm of healthcare technology has undergone remarkable advancements. The convergence of cutting-edge technologies with healthcare has opened up a vast array of possibilities, ranging from real-time monitoring of vital signs through wearable devices to the anticipation of disease outbreaks using AI systems. Looking ahead, it appears that the potential for innovation in healthcare technology knows no bounds. According to latest data, the global healthcare technology market is projected to experience substantial growth, expanding from $371 billion in 2022 to $852 billion in 2027.

Leading the charge in this thriving sector are the recipients of this year’s awards. These companies represent a diverse spectrum of entities, including well-established, widely recognized corporations and emerging, yet rapidly expanding enterprises. Nonetheless, what unites these trailblazing companies chosen for this year’s roster is their shared commitment to transforming our daily lives and reshaping our approach to a fundamental aspect that affects us all profoundly: our health.

Among this year’s recipients of awards, we have RXNT, a true trailblazer in the ambulatory healthcare technology arena. RXNT’s platform has facilitated the transmission of over 100 million prescriptions, facilitated over 10 million signed encounters, and consistently processed an average of $300 million in claims each year.

Furthermore, this year we are extending our recognition to Moderna, a rapidly expanding company that has consistently secured its status as a leading biopharmaceutical employer, a feat acknowledged by Science Magazine for eight consecutive years. Although many may be more familiar with Moderna for its mRNA technology, which led to the development and authorization of one of the earliest COVID-19 vaccines during the global pandemic. Lastly, we have Bio-Rad Laboratories, a company whose position as a prominent player in the life science research and clinical diagnostics markets earned it $2.8 billion in revenues for 2022.

Please join us in recognizing The Top 100 Healthcare Technology Companies of 2023.

This year’s awardees include Access Healthcare, PCI Pharma Services, Tebra, Relias, symplr, Enovis, Ascom, Zynex Medical, Nextech, Loftware, PartsSource, Viz.ai, BrightInsight, Welldoc, Scientist.com, Tomorrow Health, ModuleMD, RXNT, kontakt.io, Apixio, VirtualHealth, Molli Surgical, Cambrian Bio, Spartan Medical, American Health Technology Group, eVideon, Bastion Health, Neuro42 and Vizzia Technologies, among other notable companies. To view the full list, visit https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on healthcare technology and the various companies, executives and investors that make up the sector.

Media Contact

EDITOR, The Healthcare Technology Report, 1 609-365-7014, [email protected], https://thehealthcaretechnologyreport.com/

SOURCE The Healthcare Technology Report

Science: Biology

INSTANDA Honored with 2023 PropertyCasualty360 Insurance Luminary Award

Leave a comment


Global digital platform provider for carriers and MGAs has been named to PropertyCasualty360’s Insurance Luminaries Class of 2023 in the Technology category.

NEW YORK, Oct. 18, 2023 /PRNewswire-PRWeb/ — INSTANDA, a digital platform provider that enables carriers and MGAs to create, build and implement complex insurance products with agility, has been named to PropertyCasualty360’s Insurance Luminaries Class of 2023 in the Technology category.

“Today’s top insurance organizations recognize the industry’s history and purpose while embodying contemporary processes and services,” says NU Property & Casualty Executive Editor Elana Ashanti Jefferson. “My colleagues and I are thrilled to be able to recognize pace-setting insurance organizations, programs, practices, teams and individuals as part of the annual NU PropertyCasualty360 Luminaries recognition program.”

This recognition celebrates innovation in the property and casualty insurance industry, spotlighting the top professionals, teams, organizations, programs, practices and products that strive to modernize and humanize the business. The 2023 honorees were selected by a panel of industry experts based on how well they stated and achieved goals with regards to the nomination category; how impactful their work has been; how dedicated the nominee has been in furthering modernization and humanization of the P&C insurance business; and how committed and dedicated the nominee has been to high ethical standards, service and excellence.

“INSTANDA is honored to accept this recognition. We share a vision to help insurance organizations innovate at scale with a fully customizable, user-friendly no-code platform,” said Geoff Keast, INSTANDA’s VP of Sales. “Our founders worked on the buyer side of technology for years and knew what was missing in the marketplace. INSTANDA was created to address this market gap. To have the work of our company recognized as leading the much-needed, thoughtful modernization of the insurance industry is a distinct honor and exceptionally gratifying.”

About INSTANDA
INSTANDA offers a complete digital platform for innovative insurers, including more than 80 carriers, MGAs and brokers in Europe, North America, UK, Japan, Latin America, Africa, the Middle East and Australia. Named one of the world’s Top 50 InsurTechs for 2023 by CB Insights, INSTANDA is the insurance industry’s first no-code core insurance platform that allows innovative insurers to digitize their entire business as well as break into new markets with quick-to-market new products while simultaneously overcoming the drawbacks of legacy IT systems and driving digital transformation. For more information, please visit instanda.com/us/ and follow us @instandaF2X on Twitter and INSTANDA on LinkedIn.

Media Contact

Rod Hughes, INSTANDA, (610) 559-7585, r[email protected]

SOURCE INSTANDA



Health

New research led by Mays Cancer Center reveals how mutations in BRCA1 affect cancer susceptibility in women

Leave a comment


Study led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio offers means to assess whether patients with many BRCA1 gene mutations would require a mastectomy for cancer prevention, or if they could be treated with current available targeted cancer drugs.

SAN ANTONIO, Oct. 18, 2023 /PRNewswire-PRWeb/ — Three decades after discoveries linking mutations in the BRCA1 gene to breast and ovarian cancer susceptibility, research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has pinpointed the molecular mechanism by which a large portion of these mutations cause cancers in women.

The discovery, unveiled in an Oct. 4 research article in the journal Molecular Cell, is poised to assist researchers in developing drugs to battle breast and ovarian cancers and to help identify women who are at an elevated risk of developing these cancers, according to the authors.

The article is titled, “Crucial Roles of the BRCA1-BARD1 E3 Ubiquitin Ligase Activity in Homology-Directed DNA Repair,” with lead author Weixing Zhao, PhD, assistant professor of biochemistry and structural biology, the Greehey Children’s Cancer Research Institute (GCCRI) and Mays Cancer Center at UT Health San Antonio.

Other corresponding authors include Sandeep Burma, PhD, professor and vice chair (research) of neurosurgery at UT Health San Antonio and Mays Cancer Center, and Rachel E. Klevit, PhD, professor of biochemistry at the University of Washington. Additional researchers are from GCCRI and the departments of biochemistry and structural biology, neurosurgery, obstetrics and gynecology, and molecular medicine at UT Health San Antonio; University of Washington; Dartmouth College; Colorado State University; and The University of Texas Southwestern Medical Center.

While it’s established that BRCA1 (Breast Cancer Gene 1) in conjunction with an essential partner gene BARD1 (BRCA1 Associated Ring Domain 1) act as a safeguard against cancer, how exactly it accomplishes this has been a matter of debate. One vital function of BRCA1, known as E3 ligase activity that was first reported in 1999, has been particularly spotlighted.

This activity allows BRCA1 to regulate key proteins involved in DNA repair and other biological processes by tagging these proteins with “ubiquitin moieties,” which refer to tiny molecular tags that can be attached to proteins inside our living cells. These tags are like little flags that signal different actions for those proteins.

However, in 2011, researchers using a specially designed variant of the BRCA1 gene (I26A), which was thought to lack the E3 ligase activity, concluded that this activity wasn’t necessary for BRCA1’s ability to prevent cancer. This conclusion remained at odds with the fact that a large number of BRCA1 mutations seen in patients actually fall within the E3 ligase domain of BRCA1.

“That work and many subsequent studies using the same mutant have shaped the field and its research for more than a decade, with more than 200 papers published using the BRCA1-I26A mutant,” Zhao said. “However, critical validation showing that the mutant is indeed ‘ligase-dead’ in a physiological context has never been reported.”

So, the team set about generating highly purified full-length BRCA1-BARD1 and several of its known cellular substrates that allowed them to establish robust BRCA1-BARD1-mediated in vitro ubiquitylation reactions. “This essentially not only allowed us to finally put underlying assumptions that had gone unquestioned for decades to the test,” Zhao said, “but we also sifted through a bunch of mutations to find the one that really shuts down the E3 ligase activity.”

Using this approach, the researchers found that the mutant that was used in previous studies and believed to lack E3 ligase activity actually retains a strong level of this activity, challenging the longstanding belief that this activity of BRCA1 is not required for suppressing tumor formation. Furthermore, by finding a truly inactive mutant, they re-examined whether and how this activity is involved in DNA repair and tumor suppression.

“With this specific non-working mutant, our experiments clearly demonstrated that this enzyme is crucial in several stages of DNA repair,” Zhao said. “Additionally, we found that the process of BRCA1-BARD1 adding ubiquitin to histones plays an important role in repairing DNA breaks, further strengthening our conclusion about this E3 ligase activity of BRCA1.”

Burma added, “Our findings necessitate reinterpretation of scores of previous studies involving the BRCA1-I26A mutant and provide us with a fresh perspective on the tumor-suppressor roles of BRCA1.”

Crucial Roles of the BRCA1-BARD1 E3 Ubiquitin Ligase Activity in Homology-Directed DNA Repair

Meiling Wang, Wenjing Li, Nozomi Tomimatsu, Corey H. Yu, Jae-Hoon Ji, Salvador Alejo, Samuel R. Witus, Dauren Alimbetov, O’Taveon Fitzgerald, Bo Wu, Qijing Wang, Yuxin Huang, Yaqi Gan, Felix Dong, Youngbo Kwon, Gangadhara R. Sareddy, Tyler J. Curiel, Amyn A. Habib, Robert Hromas, Carolina dos Santos Passos, Tingting Yao, Dmitri N. Ivanov, Peter S. Brzovic, Sandeep Burma, Rachel E. Klevit, Weixing Zhao

First published: Oct. 4, 2023, Molecular Cell

Link to article: https://www.sciencedirect.com/science/article/pii/S1097276523007347?dgcid=coauthor

The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is one of the country’s leading health science universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions, graduate biomedical sciences and public health have graduated more than 42,200 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.

The Mays Cancer Center at UT Health San Antonio is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. To learn more, visit https://cancer.uthscsa.edu.

Stay connected with the Mays Cancer Center on Facebook, Twitter, LinkedIn, Instagram and YouTube.

Media Contact

Steven Lee, The University of Texas Health Science Center at San Antonio, 210-450-3823, [email protected], news.uthscsa.edu

SOURCE The University of Texas Health Science Center at San Antonio

Society: Christianity

A New Supplement for Women’s Whole Health, Skin and Hair Enhanced by Cognizin® Citicoline

Leave a comment


The innovative, full-spectrum nutraceutical formulation features an all-in-one powder blend that optimizes health and increases women’s overall quality of life.

NEW YORK, Oct. 18, 2023 /PRNewswire-PRWeb/ — Cybele, a venture-backed, science-driven health brand, recently launched an all-in-one, daily dose supplement powder blend featuring science-backed Kyowa Hakko’s Cognizin® Citicoline for focus and attention, as part of their formulation to support women’s whole health including digestion, mood, immunity, energy levels sleep and beauty.

The new supplement powder is available in delicious vanilla and rich chocolate flavors, and blends very well with coffee, yogurt, smoothies, and any other drinks or foods of preference.

Given the numerous women experiencing nutrient deficiencies, hormone imbalances, while grappling with stress, poor sleep, digestive issues, brain fog, and premature aging, Goddess enters the market at a perfect time, to provide a full spectrum of the essential daily nutrients that women need to thrive inside-out.

“We are very excited about this venture with Cybele,” said Karen Todd, MBA, RD, Vice President of Global Brand Marketing, Kyowa Hakko USA, Inc., adding, “Women’s health research has been vastly underfunded for decades when compared to spending on conditions that affect men. Supporting women’s health with a whole-body approach to living is essential for women and a top priority for us.”

The Goddess features a patented formula designed to fill diet gaps, boost energy and metabolism, build immunity, improve gut health, enhance cognitive performance, decrease bloating, promote hormonal balance, improve skin overall appearance, strengthen hair and nails, and help reduce stress levels by regulating cortisol.

According to Irene Bataller, Cybele’s founder, “Facing a chronic condition and an adverse reaction to medications, I yearned for something both simple and genuine. This led me to create Cybele. The Goddess is our answer: a comprehensive advantage for women.”

To learn more about Cognizin® Citicoline, please visit, https://cognizin.com.

About Cognizin® Citicoline:
Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and branded form of Citicoline, a natural substance made endogenously in the body and especially vital to brain health. Citicoline is a potent brain-health nutrient. A proprietary form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, attention, and recall. Cognizin® is manufactured through a fermentation process to yield high quality and high purity. Cognizin® is also highly stable, GRAS, ultra-pure, and allergen-free. For more information on Cognizin®, visit Cognizin.com.

About Kyowa Hakko USA:
Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com/.

About Cybele:
Women-owned and women-driven, Cybele was born to revolutionize the highly fragmented and inconvenient health and beauty supplement industry with all-natural, holistic, convenient, and highly effective solutions. At Cybele, we firmly believe that health forms the foundation for a fulfilling and vibrant life. Our mission is to empower women to conquer their health and unlock their full potential inside and out, enabling them to thrive in every aspect of their lives.

Media Contact: Giselle Chollett [email protected] 917.386.7116. 

Media Contact

Maria Stanieich, Kyowa Hakko USA, 5514829968, [email protected], https://kyowa-usa.com/

SOURCE Cybele

Health: Abortion

Young Living Highlights Partnership with Hope for Justice During Anti-Slavery Week

Leave a comment


The weeklong observance runs October 16–23, with Anti-Slavery Day on October 18, and aims to educate audiences about the 49.6 million individuals currently trapped in situations of slavery. Over half of those are trapped in forced or bonded labor and cannot refuse or leave work because of threats, coercion, violence, and abuse of power. A growing concern, the number of people in conditions of modern-day slavery has increased by 10 million in the last five years.

“Young Living is honored to participate in this year’s awareness campaign for Anti-Slavery Week as part of the Slave-Free Alliance,” said Michelle Shin, EVP, Supply Chain. “We believe in a world where everyone can thrive with dignity, and we are committed to taking actionable steps against all forms of modern slavery and exploitation.”

Young Living takes pride in fostering a collective commitment to social impact that transcends the confines of the D. Gary Young, Young Living Foundation. The Supply Chain team at Young Living is committed to protecting the rights of those most vulnerable in the supply chain through its partnership and affiliation with the Slave-Free Alliance. The sourcing and manufacturing of goods and services should never use child labor or conditions that restrict personal freedoms.

“Slave-Free Alliance is proud to partner with Young Living to support its work to protect those most vulnerable in its global operations and supply chain. Young Living continues to stretch its work beyond compliance and transparently address risks of modern slavery and labor exploitation.” said Rachel Hartley, consultancy director, Slave-Free Alliance. “We’re thrilled to recognize Anti-Slavery Week and incredibly grateful for Young Living’s support of our parent charity, Hope for Justice. Together, we’re committed to creating long-lasting social impact.”

This week serves as a tangible manifestation of Young Living’s ongoing mission of empowering wellness, purpose, and abundance for communities around the world. Last year, the Young Living Foundation and Hope for Justice created an online course to prevent the exploitation of children and create safer spaces online.

Young Living also announced that anyone who donates to Hope for Justice during Anti-Slavery Week will receive a 5 ml bottle of Valor® essential oil blend.

To learn more about Slave-Free Alliance and Anti-Slavery Week, visit slavefreealliance.org.

About Young Living Essential Oils

Young Living Essential Oils, LC, based in Lehi, Utah, is the world leader in essential oils, offering the highest quality oil-infused products available. Young Living takes its industry leadership seriously, setting the standard with its proprietary Seed to Seal® quality commitment. This guiding principle helps Young Living protect the planet and provide authentic products that its Brand Partners and Customers can feel confident using and sharing with friends and family. Young Living’s products—sourced from corporate-owned farms, partner farms, and other trusted suppliers—not only support a healthy lifestyle but also provide opportunities for over 6 million global Brand Partners to find a sense of purpose and whole-life wellness by aligning their work with the Young Living values and passions. For more information, visit YoungLiving.com, follow @youngliving on Instagram, or like us on Facebook.

Media Contact

Maria Coder, Young Living Essential Oils, 954-379-2115, [email protected], https://www.youngliving.com/

SOURCE Young Living Essential Oils



Health

VGI Medical, LLC Announces The Launch of the new SiJoin® Transfixing Triangular Trabecular Titanium (T4) Implant System, for Sacroiliac Joint Transfixation, at NASS 2023

Leave a comment



VGI Medical, LLC announces the launch of the new SiJoin® Transfixing Triangular Trabecular Titanium (T4) Implant System. The SiJoin® T4 System is the next evolution of the successful SiJoin® Transfixing Implant Fusion Device, proven for over 10 years, and will be presented at NASS 2023 in Los Angeles, Booth 2601. VGI’s superior engineering and testing has allowed them to design a titanium alloy implant for use in alleviating sacroiliac joint pain and create a simplified process for the surgeon.

LARGO, Fla., Oct. 18, 2023 /PRNewswire-PRWeb/ — VGI Medical, LLC launches the new US FDA 510(k) cleared SiJoin® Transfixing Triangular Trabecular Titanium (T4) Implant System. The transfixing SiJoin® T4 Implant is made from Ti-6AI-4V ELI titanium alloy using an additive manufacturing process, where the porous trabecular construction is engineered to mimic cancellous bone structure. The implant has an engineered lattice design to achieve 500-700 mm pores, and has undergone post processing to create micro and nano surface structures facilitating the proliferation of osteoblast adhesion and bony in-growth. The SiJoin® T4 Implant is engineered with a dual geometric shape designed to be simultaneously positioned within the illium and sacrum, through the respective cortical wall, providing high surface area contact for fixation. The implant is held against rotation via the stabilizer fins positioned between the opposing illium and sacrum surfaces, and the non-circular cross-section of the main body. The patented novel design of the SiJoin® T4 Implant fixes the sacrum and ilium relative to one another, maintaining the anatomical spacing of the SI joint, providing mechanical support by transfixing the SI joint while biologic fusion occurs.